SEC Form 4 · accession 0001144204-18-019049
Bionik Laboratories Corp. · BNKL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Remi Gaston-Dreyfus
Director · 10% Owner
Period of report
Mar 31, 2018
Accepted (ET)
Apr 3, 2018 · 6:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001508381
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 31, 2018 | C | 63,197,149 | $0.0625 | A | 75,463,389 | I | Shares held through RGD Investissements |
| Common StockF2 | Mar 31, 2018 | C | 12,266,240 | $0.0625 | A | 75,463,389 | I | Shares held through Lombard International Assurance SA |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantF3 | $0.0625 | Mar 31, 2017 | A | 1,760,704 | A | Mar 31, 2018 | Mar 31, 2022 | Common Stock | 1,760,704 | 3,361,344 | I |
| WarrantF3 | $0.0625 | Mar 31, 2017 | A | 1,600,640 | A | Mar 31, 2018 | Mar 31, 2022 | Common Stock | 1,600,640 | 3,361,344 | I |
| WarrantF3 | $0.0625 | Aug 14, 2017 | A | 5,858,343 | A | Mar 31, 2018 | Aug 14, 2022 | Common Stock | 5,858,343 | 5,858,343 | I |
Explanation of responses
- F1On March 31, 2018, an aggregate amount of $4,931,644 in convertible promissory notes converted in accordance with their terms into (i) 63,197,149 shares of the Issuer's common stock, and (ii) 15,740,728 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance.
- F2On March 31, 2018, an aggregate amount of $766,333 in convertible promissory notes converted in accordance with their terms into 12,266,240 shares of the Issuer's common stock.
- F3As of each of the transaction dates, the number of shares of common stock underlying warrants and the exercise price were not yet determinable. Such number of shares and exercise price were each determined on March 31, 2018.